Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Confirm inflammatory relapse, find secondary causes and use slow, steroid-sparing escalation to prevent repeated flares and constriction.
Recurrence is often immune-mediated, but the diagnostic threshold still matters. Symptoms can persist after inflammation resolves, while TB, malignancy and systemic disease can masquerade as idiopathic relapse.
The treatment principle is to extinguish objective inflammation and withdraw one drug at a time, slowly. Colchicine reduces recurrence; corticosteroid exposure and rapid tapers can create dependency.
CMR is particularly useful when conventional criteria are equivocal and in selecting anti-inflammatory escalation. Chronic effusion or constrictive physiology follows a different drainage/surgical pathway.
After an apparently idiopathic or viral first episode, persistent innate immune activation can trigger renewed sterile pericardial inflammation despite no ongoing detectable infection.
A short initial course, premature taper or poor adherence may leave inflammation incompletely controlled. Early corticosteroid use and rapid tapering are associated with recurrence and treatment-dependent flares.
Tuberculosis and bacterial infection become especially important with fever, exposure, immunosuppression or a complicated effusion because immunosuppression could worsen an untreated pathogen.
Autoimmune disease, malignancy, renal failure, post-cardiac injury and some medicines can sustain pericardial injury; an atypical or refractory course should prompt targeted investigation.
An infectious, immune, malignant, metabolic or post-injury trigger damages pericardial mesothelial surfaces and exposes inflammatory signals to the innate immune system.
Cytokine-driven inflammation causes pericardial oedema, friction between inflamed layers and sometimes exudative fluid accumulation, producing positional pleuritic pain and systemic inflammatory markers.
Persistent or renewed immune activation, including during treatment withdrawal, can produce recurrent flares; ongoing symptoms without objective inflammation may instead reflect non-inflammatory pain.
Continuing fluid production may create a chronic effusion, while repeated injury and healing can lead to adhesion, fibrosis, thickening or calcification.
Rapid or excessive fluid accumulation can restrict chamber filling as tamponade; a rigid scarred pericardium can cause ventricular interdependence and chronic constrictive physiology.
Return of typical pain with rub, ECG change, new/worsening effusion, CRP rise or pericardial oedema/LGE after remission.
Symptoms recur during taper or never fully settle for more than 4-6 weeks but less than 3 months.
Disease beyond 3 months may be inflammatory, an isolated effusion or established constriction; distinguish these before escalating drugs.
Persistent fever, night sweats, weight loss, immunosuppression, cancer, TB exposure, renal failure, autoimmune features or post-procedure timing.
Rising JVP, tachycardia, pulsus paradoxus, hypotension or echo chamber collapse is an emergency irrespective of chronicity.
Ascites, oedema, Kussmaul sign, pericardial knock or ventricular interdependence needs specialist constriction assessment.
Persistent chest-wall, pleural or sensitisation pain without raised inflammatory markers, new effusion or imaging inflammation should not automatically be labelled another pericarditis flare.
Pressure-like pain with regional ischaemic ECG change and a dynamic troponin rise favours acute myocardial ischaemia; pericarditis more often causes positional pain and widespread electrical change.
Troponin elevation, ventricular dysfunction or ventricular arrhythmia raises concern for myocardial involvement, which changes monitoring, exercise advice and the required imaging pathway.
New dyspnoea, hypoxaemia, haemoptysis, unilateral deep-vein signs or right-heart strain should prompt the pulmonary embolism pathway rather than assuming recurrent pericardial pain.
Focal tenderness, pain reproducible by movement, cough or a local pleural process supports a non-pericardial source, particularly when inflammatory cardiac tests remain unchanged.
Ongoing inflammation or an untreated secondary cause may lead to fluid accumulation. When intrapericardial pressure limits diastolic filling, hypotension and obstructive shock can develop rapidly.
Repeated or severe inflammation can occasionally produce a non-compliant fibrotic pericardium, limiting ventricular filling and causing raised venous pressure, ascites, oedema and congestive organ dysfunction.
Coexisting myocardial inflammation can cause ventricular dysfunction, troponin release or arrhythmia and requires a distinct myopericarditis assessment and follow-up pathway.
Frequent reactivation, especially during corticosteroid tapering, can prolong immunosuppression, impair activity and quality of life, and expose patients to cumulative treatment adverse effects.
Failure to recognise tuberculosis, bacterial infection, malignancy or systemic autoimmune disease can permit both pericardial deterioration and progression of the underlying illness.
Pain can persist from pleural, chest-wall or sensitisation mechanisms after inflammation resolves; CMR helps prevent endless immunosuppression.
Withdraw steroids first, then NSAID/aspirin, with colchicine last so the effect of each change remains interpretable.
Relapses often occur around prednisolone 10-15 mg/day, so reductions here may need to be very small and widely spaced.
Abrupt discontinuation can relapse; specialist taper follows sustained clinical, CRP and often imaging remission.
A long-standing effusion can be non-inflammatory; repeated NSAIDs will not correct tamponade physiology or malignancy.
Calling pain alone a recurrent inflammatory episode without objective corroboration.
Giving a short high-dose steroid burst before excluding TB or bacterial disease.
Tapering steroids, NSAID and colchicine together.
Starting IL-1 blockade without infection screening and specialist follow-up.
Treating chronic effusion repeatedly with anti-inflammatories while missing tamponade, malignancy or constriction.
Your practice draft is saved in this browser.
A patient with objectively active recurrent idiopathic pericarditis repeatedly relapses below prednisolone 12.5 mg despite 8 months of adherent colchicine. Infection and secondary causes have been excluded. What is the best next step?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Renal injury, ulcer/bleeding, fluid retention, hypertension and late pregnancy; reassess anticoagulant and cardiovascular context.
In mild or moderate renal or hepatic impairment use 0.5 mg once daily; severe impairment is contraindicated. Do not combine with strong CYP3A4/P-gp inhibitors when renal or hepatic function is impaired, and reduce or interrupt treatment even with normal function according to the interacting medicine. Monitor GI intolerance, cytopenia and myopathy.
Increases recurrence/dependency, infection, glucose, BP, bone and psychiatric risk; never use to mask untreated bacterial or TB pericarditis.
Screen for infection/TB and review vaccination; neutropenia, hepatic effects and injection reactions. Do not start during active serious infection.